Semaglutide in Comorbid Schizophrenia Spectrum Disorder and Obesity
Status:
Not yet recruiting
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
Rates of obesity in patients with schizophrenia-spectrum disorder (SSD)s have reached
epidemic proportions, with established contributing effects of antipsychotic (AP)
medications. Among agents approved for chronic weight management, glucagon-like peptide-1
receptor agonists (GLP-1RA) are associated with reductions in cardiovascular mortality, with
recent FDA approval for once weekly semaglutide for this indication. This study will
investigate whether semaglutide is effective in reducing body weight in overweight or obese
individuals with SSDs who are on APs and do not demonstrate adequate weight loss on metformin
(the first line treatment for weight loss in SSDs).